Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.37 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.34 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25907603 | 0.82 | CYP17A1 (0.37) | LMNABRD9PSMB8RXFP1ELANE | |
| SCHEMBL7396214 | 0.80 | KDM4E (0.47) | KDM4EALDH1A1LMNAHSD17B10MAPT | |
| SCHEMBL25032479 | 0.79 | PSMB8 (0.34) | LMNABRD9PSMB8RXFP1CYP17A1 | |
| SCHEMBL5495463 | 0.78 | SMN1; SMN2 (0.44) | KDM4EALDH1A1LMNAMAPTCA1 | |
| SCHEMBL29208185 | 0.77 | ATR (0.42) | KDM4EALDH1A1HSD17B10BRD9RXFP1 | |
| SCHEMBL30317135 | 0.77 | MRGPRX1 (0.46) | KDM4EALDH1A1BRD9RXFP1 | |
| SCHEMBL7949833 | 0.77 | MRGPRX1 (0.46) | KDM4EALDH1A1BRD9RXFP1 | |
| SCHEMBL28210980 | 0.76 | BRD9 (0.39) | BRD9PSMB8RXFP1ATRELANE | |
| SCHEMBL26148249 | 0.75 | CA12 (0.40) | KDM4EALDH1A1LMNAHSD17B10BRD9 | |
| SCHEMBL30882154 | 0.74 | AAK1 (0.37) | KDM4EBRD9PSMB8ATRCYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528785-B2 | MDM2 degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20240424110-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-12-26 | — | — | US | disclosed |
| US-11932624-B2 | MDM2 degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| CN-115776887-A | MDM2 degrading agents and uses thereof | 凯麦拉医疗公司 | 2023-03-10 | — | — | CN | disclosed |
| EP-4121043-A1 | MDM2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| WO-2021188948-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| WO-2021188948-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, TP53, MDM4 | KDM4E 1073/4885ALDH1A1 1804/4885LMNA 2219/4885 |
| US-20240424110-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, USP2, MYCBP2 | KDM4E 323/4885ALDH1A1 2946/4885LMNA 3419/4885 |
| US-12528785-B2 | MDM2 degraders and uses thereof | MDM2, ADRM1, RBX1 | KDM4E 650/4885ALDH1A1 2101/4885LMNA 3086/4885 |
| US-11932624-B2 | MDM2 degraders and uses thereof | MDM2, TP53, MDM4 | KDM4E 1073/4885ALDH1A1 1804/4885LMNA 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.